Tempus AI (TEM) said Wednesday it has entered a strategic collaboration with Boehringer Ingelheim to advance the latter's cancer pipeline.
Financial terms weren't disclosed.
Under the new, multi-year partnership, Boehringer will have access to Tempus' de-identified database which has molecular, clinical, and imaging data, and its analytical platform, Lens, Tempus added.
The parties intend to identify data derived from patient groups for biomarker development and patient stratification, and develop drug combination hypotheses, the company said.
Tempus' stock was up nearly 3% in recent Wednesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.